PURPOSE: The goals of this study were to determine if single-nucleotide polymorphisms in DNA damage repair genes and cell cycle regulating genes affect clinical response to combined gemcitabine radiation therapy and the overall survival (OS) of patients with pancreatic cancer. EXPERIMENTAL DESIGN: We evaluated six single-nucleotide polymorphisms of the ATM, ATM and Rad3-related (ATR), CHEK1, and CHEK2 genes in 119 patients with potentially resectable pancreatic cancer who were enrolled in clinical trials at The University of Texas M. D. Anderson Cancer Center from February 1999 to January 2006, with follow-up until February 2007. Patients received neoadjuvant concurrent gemcitabine and radiation therapy with or without gemcitabine-cisplatin induction therapy. Genotypes were determined and tested for associations with OS by Kaplan-Meier estimation, the log-rank test, and Cox regression analysis. P values of <or=0.05 were considered significant. RESULTS: The ATM G60A and CHEK1 G35A genotypes were significant (P<0.05), and the ATR C340T genotype borderline significantly (P=0.079) associated with OS. The hazard ratio of CHEK1 35AA was 2.01 (95% confidence interval, 1.20-3.37; P=0.007) compared with CHEK1 35GG/GA with adjustments for race, sex, diabetes status, CA19-9 level, and success of tumor resection. A significant combined genotype effect was observed between ATM 60GA/GG, ATR 340CT/CC, and CHEK1 35AA with median OS times of 31.0, 16.2, and 10.5 months for patients carrying <or=1, 2, and 3 deleterious alleles, respectively (P=0.004). CONCLUSIONS: These observations suggest that polymorphic variations of DNA damage response genes affect clinical response to gemcitabine radiation therapy and OS of patients with resectable pancreatic cancer.
PURPOSE: The goals of this study were to determine if single-nucleotide polymorphisms in DNA damage repair genes and cell cycle regulating genes affect clinical response to combined gemcitabine radiation therapy and the overall survival (OS) of patients with pancreatic cancer. EXPERIMENTAL DESIGN: We evaluated six single-nucleotide polymorphisms of the ATM, ATM and Rad3-related (ATR), CHEK1, and CHEK2 genes in 119 patients with potentially resectable pancreatic cancer who were enrolled in clinical trials at The University of Texas M. D. Anderson Cancer Center from February 1999 to January 2006, with follow-up until February 2007. Patients received neoadjuvant concurrent gemcitabine and radiation therapy with or without gemcitabine-cisplatin induction therapy. Genotypes were determined and tested for associations with OS by Kaplan-Meier estimation, the log-rank test, and Cox regression analysis. P values of <or=0.05 were considered significant. RESULTS: The ATMG60A and CHEK1G35A genotypes were significant (P<0.05), and the ATRC340T genotype borderline significantly (P=0.079) associated with OS. The hazard ratio of CHEK1 35AA was 2.01 (95% confidence interval, 1.20-3.37; P=0.007) compared with CHEK1 35GG/GA with adjustments for race, sex, diabetes status, CA19-9 level, and success of tumor resection. A significant combined genotype effect was observed between ATM 60GA/GG, ATR 340CT/CC, and CHEK1 35AA with median OS times of 31.0, 16.2, and 10.5 months for patients carrying <or=1, 2, and 3 deleterious alleles, respectively (P=0.004). CONCLUSIONS: These observations suggest that polymorphic variations of DNA damage response genes affect clinical response to gemcitabine radiation therapy and OS of patients with resectable pancreatic cancer.
Authors: Ellen L Goode; Alison M Dunning; Bettina Kuschel; Catherine S Healey; Nicholas E Day; Bruce A J Ponder; Douglas F Easton; Paul P D Pharoah Journal: Cancer Res Date: 2002-06-01 Impact factor: 12.701
Authors: Q Liu; S Guntuku; X S Cui; S Matsuoka; D Cortez; K Tamai; G Luo; S Carattini-Rivera; F DeMayo; A Bradley; L A Donehower; S J Elledge Journal: Genes Dev Date: 2000-06-15 Impact factor: 11.361
Authors: Sara Gutiérrez-Enríquez; Marie Fernet; Thilo Dörk; Michael Bremer; Anthony Lauge; Dominique Stoppa-Lyonnet; Norman Moullan; Sandra Angèle; Janet Hall Journal: Genes Chromosomes Cancer Date: 2004-06 Impact factor: 5.006
Authors: Jason A Willis; Sara H Olson; Irene Orlow; Semanti Mukherjee; Robert R McWilliams; Robert C Kurtz; Robert J Klein Journal: Clin Cancer Res Date: 2012-06-04 Impact factor: 12.531
Authors: Hongmei Zeng; Herbert Yu; Lingeng Lu; Dhanpat Jain; Mark S Kidd; M Wasif Saif; Stephen J Chanock; Patricia Hartge; Harvey A Risch Journal: Pancreas Date: 2011-07 Impact factor: 3.327
Authors: Remko Prevo; Emmanouil Fokas; Philip M Reaper; Peter A Charlton; John R Pollard; W Gillies McKenna; Ruth J Muschel; Thomas B Brunner Journal: Cancer Biol Ther Date: 2012-07-24 Impact factor: 4.742
Authors: Fabian Dominik Mairinger; Robert Werner; Elena Flom; Jan Schmeller; Sabrina Borchert; Michael Wessolly; Jeremias Wohlschlaeger; Thomas Hager; Thomas Mairinger; Jens Kollmeier; Daniel Christian Christoph; Kurt Werner Schmid; Robert Fred Henry Walter Journal: Virchows Arch Date: 2017-05-02 Impact factor: 4.064
Authors: Xiaoqun Dong; Li Jiao; Yanan Li; Douglas B Evans; Huamin Wang; Kenneth R Hess; James L Abbruzzese; Donghui Li Journal: J Clin Oncol Date: 2009-02-23 Impact factor: 44.544
Authors: David O Azorsa; Irma M Gonzales; Gargi D Basu; Ashish Choudhary; Shilpi Arora; Kristen M Bisanz; Jeffrey A Kiefer; Meredith C Henderson; Jeffrey M Trent; Daniel D Von Hoff; Spyro Mousses Journal: J Transl Med Date: 2009-06-11 Impact factor: 5.531